AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

AbbVie Inc. reported Q2 2025 sales of $15.42 billion, surpassing consensus, though adjusted EPS of $2.97 missed estimates. The company raised its full-year 2025 adjusted EPS guidance to $11.88-$12.08, which remains below analyst expectations. Despite anticipated moderation in net pricing and ongoing Humira erosion, analysts like Guggenheim and Morgan Stanley maintain positive outlooks, citing robust volume growth from key products such as Skyrizi and Rinvoq, which are tracking ahead of prior long-term targets, leading to increased price targets and a 3.24% rise in ABBV stock.

Analysis

AbbVie's second-quarter 2025 financial results presented a mixed but ultimately constructive picture, with the market focusing on forward-looking growth drivers over near-term earnings pressure. The company reported a 6.6% year-over-year increase in sales to $15.42 billion, comfortably beating the $14.98 billion consensus and signaling robust top-line performance. However, this was contrasted by an adjusted EPS of $2.97, which, despite growing 12.1%, missed the consensus of $3.23. Similarly, while AbbVie raised its full-year 2025 adjusted EPS guidance to $11.88–$12.08, the revised range remains below the analyst estimate of $12.24. The positive market reaction, evidenced by a 3.24% stock price increase, appears driven by analyst confidence in the company's growth portfolio. Both Guggenheim and Morgan Stanley upgraded their price targets, citing the exceptional volume growth of key products Skyrizi and Rinvoq, which are tracking ahead of long-term targets and effectively offsetting the steeper-than-expected erosion of Humira sales. Analysts anticipate management will raise its long-term guidance and view potential headwinds from the Inflation Reduction Act's Part D Redesign as manageable.

Key Decisions for Investors

• Investors should weigh the strong volume growth from key drugs Skyrizi and Rinvoq, which is driving analyst price target increases, against the ongoing EPS pressure from Humira's decline and a full-year guidance that still trails market consensus.
• Monitor future company reports for an anticipated upward revision of long-term targets for the growth portfolio, as analysts at Guggenheim believe current performance is well ahead of prior guidance and will be a key catalyst.
• Factor in the potential for moderating net drug prices in the second half of the year and the regulatory risk from the Inflation Reduction Act, though current analyst consensus suggests these headwinds are unlikely to derail the core growth narrative.
• Given the bullish analyst ratings and increased price targets from both Guggenheim and Morgan Stanley, consider that the market is prioritizing the company's successful portfolio transition over the mixed quarterly earnings print.